Syndax Pharmaceuticals Inc SNDX.OQ SNDX.O is expected to show a rise in quarterly revenue when it reports results on March 3 for the period ending December 31 2024
The New York City-based company is expected to report revenue of $85.912 million, according to the mean estimate from 13 analysts, based on LSEG data.
LSEG's mean analyst estimate for Syndax Pharmaceuticals Inc is for a loss of 23 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Syndax Pharmaceuticals Inc is $35.50, above its last closing price of $15.28.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -1.14 | -1.11 | -0.98 | Beat | 11.9 |
Jun. 30 2024 | -0.91 | -0.91 | -0.80 | Beat | 12.5 |
Mar. 31 2024 | -0.96 | -0.98 | -0.85 | Beat | 13.1 |
Dec. 31 2023 | -0.97 | -0.99 | -1.00 | Missed | -0.6 |
Sep. 30 2023 | -0.80 | -0.80 | -0.73 | Beat | 8.2 |
Jun. 30 2023 | -0.73 | -0.73 | -0.64 | Beat | 12.6 |
Mar. 31 2023 | -0.60 | -0.60 | -0.59 | Beat | 1 |
Dec. 31 2022 | -0.65 | -0.65 | -0.62 | Beat | 4.4 |
This summary was machine generated February 28 at 13:44 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.